The human cytomegalovirus (HCMV), a betaherpesvirus, is a ubiquitous human pathogen 3 causing congenital infections, and also represents a major morbidity risk for the immune 4 suppressed or immunodeficient patient (56). 5 HCMV encodes approximately 200 genes, which represent a large antigenic potential. 6 However, despite previous efforts, (59, 60), no effective vaccine could be generated so far (67). 7
Although the Towne strain was shown in numerous studies to be a safe and immunogenic 8 vaccine (1, 29, 30 ), it's immunogenicity was lower than in the wild-type (WT) virus and it failed 9 to confer immune protection against infection by natural contact (2) . Several features of HCMV 10 infection make vaccine development uniquely difficult. A large number of HCMV genes 11 modulate the innate and adaptive host immune response to the advantage of the pathogen (43, 50, 12 75). Natural CMV infection provides only partial protection and re-infection can cause congenital 13 CMV disease even in infants of mothers with pre-conceptional immunity (5, 22) . Moreover, the 14 life-long virus persistence in the state of latency with the possibility of reactivation represents a 15 safety concern when using a live attenuated herpesvirus vaccine. Finally, cytomegaloviruses are 16 characterised by strict species specificity and there is no animal model for direct studies of 17 HCMV infection and immunity in vivo. 18 and m158. Therefore, we reasoned that targeted deletion of these gene clusters may allow us to 1 test a novel concept in herpesvirus vaccinology, and generate an MCMV mutant that will be 2 immunogenic and selectively attenuated in vivo, but not in vitro. 3 A mutant lacking genes m02 to m16 showed no replication defect in vitro but was severely 4 attenuated in vivo (55). In a previous study we found the gene m143 to be essential (48). 5 Therefore, by homologous recombination of MCMV genomes maintained as BAC in E. coli (see 6 Material & Methods), we deleted the genes m01 to m17 and m144 to m158 to generate the 7 recombinant MCMV BAC p∆m01-17+m144-158. The analysis of four restriction enzyme pattern 8 using the NdeI, NotI, and EcoRV, respectively, confirmed the expected recombinant genome 9 (Fig. 1a) . 10 MEF were transfected with p∆m01-17+m144-158 DNA and virus progeny, referred to as ∆m01-11 17+m144-158-MCMV, was gained. Thus, the 32 deleted genes are dispensable for virus growth 12 in vitro. To test the stability of the significantly shortened genome, we analyzed viral DNA in 13 infected fibroblasts after several cell culture passages. Two independently transfected clones of 14 ∆m01-17+m144-158-MCMV were passaged at least 5 times on M2-10B4 cells prior to DNA 15 isolation. EcoRI restriction enzyme patterns of isolated virus DNA showed that the genome of 16 the deletion mutant had the same restriction pattern as its parental BAC (data not shown). We 17 also analyzed the stability of the locus in which the BAC vector sequence is inserted. MCMV genomes carrying the BAC sequence are believed to be oversized and thus less efficient 19 in packaging. A 500 base pair sequence belonging to m159 is repeated at both ends of the BAC-20 vector (Fig1b; black boxes), which allows homologous recombination and removal of the BAC-21 vector sequences by natural selection after a few passages (71) (Fig. 1b ; compare the first two 22 linear maps). In line with the prediction that MCMV are selected for their genome size, the BAC-23 vector sequence was not excised from ∆m01-17+m144-158-MCMV, as revealed by Southern 24 blotting upon 7 passages of the mutant in M2-10B4 cells (see Fig.1b and c) . The probe used for 1 the Southern blot was amplified by PCR on the pSN3fr template and recognizes the repeated 2 sequence and the 3' end of the BAC-vector, including the loxP sites. The BAC-DNA and viral 3 DNA were treated with PciI restriction endonuclease which cleaves within the repeat and the 3' 4 end of the BAC. Therefore there are five fragments which are recognized specifically by this 5 probe: the BAC sequence (Fig. 1b, fragment B) , the upstream and the downstream repeated 6 sequences connected to the 5' or the 3' end of the BAC-vector (Fig. 1b, B1 and B2) , the left 7 genomic fragment which contains the m158 ORF (Fig. 1b, L ) and the right genomic fragment 8 which contains the m159 ORF (Fig. 1b, R) . Due to the deletion of the m144-158 the L derived 9 fragment in the mutant ( Fig. 1b ; ∆L) shifts down from the original 2.8 Kbp to 2.4 Kbp. While the 10 BAC derived B, B1 and B2 fragments become undetectable after passaging of the reconstituted 11 WT construct ( Fig. 1c; lanes 1 and 2) , the virus stocks derived from the BAC p∆m01-17+m144-12 158 still maintain these fragments ( Fig. 1c; lanes 3 and 4) . Thus, the retention of the BAC-vector 13 sequences indicated that, in contrast to WT-MCMV, the deletion mutant virus was not selected 14 for shorter genome size. 15 16 17 ∆ ∆ ∆ ∆m01-17+m144-158-MCMV replicates to WT levels in fibroblasts, endothelial and epithelial 18 cells. To test ∆m01-17+m144-158-MCMV replication in cell-culture, we compared it to WT-19 MCMV in a multi-step growth kinetics on NIH3T3 cells. The mutant replication was comparable 20 to WT-MCMV (Fig. 2a) . We also tested the growth of the recombinant virus on the macrophage 21 cell line Ana-1, the endothelial cell line SVEC4-10 and the mammary epithelial cell line C127 22 (Fig 2b, c, d ). ∆m01-17+m144-158-MCMV replicated like WT-MCMV in endothelial and 23 epithelial cell lines, but was about 15 fold attenuated in Ana-1 macrophages. A similar 24 attenuation was seen in another macrophage line, IC-21, but this growth deficit was overcome at 1 the multiplicity of infection (MOI) of 1 (data not shown). The mutant was also not attenuated in 2 mHTC-K2, a hepatocyte cell line (data not shown). Therefore, with the exception of a moderate 3 growth deficit in macrophages, the mutant and WT-MCMV showed similar growth kinetics in 4 different cell lines. We concluded from these experiments that the lack of 32 genes and the 5 presence of the BAC cassette had a little if any effect on virus replication in vitro. 6 7 ∆ ∆ ∆ ∆m01-17+m144-158-MCMV is severely attenuated in vivo. BALB/c mice, a mouse strain 8 susceptible to MCMV(41) was used to test the virulence of ∆m01-17+m144-158-MCMV in vivo. 9
Infectious WT and mutant titers were compared in lungs, spleen, liver and salivary glands at d 5 10 and 12 post infection (p.i.). Mutant virus growth was severely attenuated in all organs at both 11 time points (Fig. 3a and b) , although some virus detected 5 days p.i. in the lungs and the spleen of 12 mice infected with ∆m01-17+m144-158, indicated that the virus was still able to colonize the 13 organs and to replicate in vivo. Moreover, infection with the mutant did not result in weight-loss, 14 a rough indicator of compromised health (data not shown) 15
16
Compromised ∆ ∆ ∆ ∆m01-17+m144-158-MCMV reactivation from latency. A hallmark of CMV 17 infection is the ability to reactivate its productive virus infection from latency upon immune 18 suppression. Therefore, there is concern that even an attenuated live CMV vaccine might 19 reactivate and cause disease under immune suppressive conditions. We tested ∆m01-17+m144-20 158-MCMV reactivation upon immune suppression. Nine months after primary infection with 21 mutant or WT-MCMV, mice were immune suppressed by antibody depletion of T-cell subsets 22 followed by gamma irradiation. 11 days later, spleen explants were co-cultivated with MEF, to 23 detect virus reactivation. Virus could be detected in mice infected with WT-MCMV, but in none 24 of the mice infected with the mutant virus (Fig. 4) . In an independent experiment, no reactivation 1 of ∆m01-17+m144-158-MCMV was observed in the liver and spleen of mice that were immune 2 suppressed by gamma irradiation at 28 d p.i. and sacrificed 7 days later, although WT-MCMV 3 reactivated in all of the control mice (data not shown). Thus, replicating ∆m01-17+m144-158-4 MCMV could not be isolated upon immune suppression. (17)) were quantified by 9 tetramer staining or by peptide stimulation followed by ICCS. Seven days after infection, the 10 mutant and the WT induced similar CD8 responses, as observed by tetramer staining (Fig. 5a) . 11
Remarkably, ICCS showed that the functional response to peptide stimulation was significantly 12 (p=0.007, Mann Whitney test) stronger in mice infected with the mutant than those infected with 13 the WT (Fig 5a) . Taken together, these results indicated that ∆m01-17+m144-158-MCMV 14 infection induced cellular responses that were functionally even stronger than the ones induced 15 by WT. 16 To test the long-term immunogenicity of ∆m01-17+m144-158-MCMV, mice were bled 16 weeks 17 following a prime/boost immunization and antibody titers to MCMV were determined by ELISA. peptide at an early and a late point after infection. Two weeks p.i., 1% of total peripheral CD8 + -1 cells were specific for this peptide in animals infected with ∆m01-17+m144-158-MCMV or WT-2 MCMV. At 6 months p.i., this percentage increased to ~4-8% in both mutant and WT-MCMV 3 infected mice. (Fig. 5c) . In mice subjected to a prime-boost protocol we observed a similar 4 proportion of tetramer positive cells at 18 weeks post priming (data not shown). Therefore, 5 different to the antibody response, ∆m01-17+m144-158-MCMV induced a specific CTL response 6 that was comparable to that induced by WT-MCMV with respect to kinetics and strength. WT-MCMV immunization strongly suppressed MCMV replication on challenge, whereas mock-14 immunized controls showed high virus titers in all of the tested organs (Fig. 6a) . Thus, 15 immunization with ∆m01-17+m144-158-MCMV and with WT-MCMV led to a comparable 16 degree of protection of mice against a challenge with WT-MCMV. 17
The poor replication of ∆m01-17+m144-158-MCMV in vivo (Fig 3) The challenge results in significantly lower MCMV titers in immunized mice than in mock-11 immunized controls, but this difference was more pronounced at week 20 than at week 4 ( Fig.  12 6c). Therefore, immunization with ∆m01-17+m144-158-MCMV resulted in CD8+ T cell 13 response and protection against WT challenge that increased over time. 14 15 ∆ ∆ ∆ ∆m01-17+m144-158-MCMV is attenuated in immunodeficient mice. Although we observed 16 no ∆m01-17+m144-158-MCMV reactivation from latency upon severe immune suppression ( Fig.  17 4), the sustained increase in antigen specific immunity after resolution of productive virus 18 infection ( were determined at day 7 and 21 p.i.. WT virus was found in all organs and increased over time 7 (Fig. 7b) . Mutant virus titers were below detection limit in most of the mice, but infectious virus 8 isolated in rare occasions at day 21 p.i. indicated that the infection with ∆m01-17+m144-158-9 MCMV was not abortive. In conclusion, our data argued that even if ∆m01-17+m144-158-10 MCMV could reactivate upon severe immune suppression, it would still be attenuated in immune 11 compromised hosts. 12
The high degree of attenuation suggested that ∆m01-17+m144-158-MCMV should not 13 harm even the most severely immunocompromised host. To test this, we infected IFNαβR Only a minority of CMV genes are essential (18) and a previous report showed that a 21 mutant MCMV, lacking a block of 15 genes in the genomic area ranging from m02 to m16, was 22 not attenuated in fibroblasts, but was severely attenuated in immune competent mice (55). Here 23 we extend this finding by showing that the loss of 32 genes, including genes m02 -m16, did not 24 affect the replication of the mutant MCMV in fibroblasts, epithelial and endothelial cell lines. We 1 observed a moderate, but consistent attenuation in cell culture at low multiplicity of infection in 2 macrophage cell lines. We explain the growth deficit in macrophage lines as a cell type specific 3 function of one of the 32 genes, which have not yet been studied in detail. 4
Several mutants lacking individual immune modulating MCMV genes have been 5 described. MCMV mutants that lack genes which inhibit MHC class I mediated peptide 6 presentation (70), or lack genes which evade the antiviral activity of NK cells (41), or lack 7 genomic regions comprising several genes with homologies to MHC-I genes (55) are all 8 attenuated in the immunocompetent host. Nevertheless, all these mutants can be rescued to WT 9 level by immune suppression of the host. Therefore, these mutants are not attenuated in the 10 immunodeficient host. We present here for the first time a MCMV mutant with a new quality. It 11 grows like WT-MCMV in vitro, but is severely attenuated even in the SCID/bg mouse which 12 lacks NK-, B-and T-cells and which is to date the mouse strain most sensitive to MCMV (38). i.e. viral dissemination, the modest loss of tropism for macrophages (Fig 2d) MCMV, a strong loss of pathogenicity, and vigorous immune protection that increases over time. 5
Moreover, the Towne and AD-169 vaccine strains showed a loss of tropism for important cell 6 types, i.e. endothelial or hemopoietic cells (57, 68). In contrast ∆m01-17+m144-158-MCMV was 7
still able to infect all tested cell types. The sites of CMV latency are still a matter of debate but 8 several reports indicate endothelial cells and hemopoietic precursor cells as sites of CMV latency 9 (26, 39). An attenuated virus which is able to infect these cells might still be able to establish 10 latency and abortive reactivation events in these cells might suffice to maintain a virus-specific 11 CTL response needed for sustained protective immunity (25). In line with this hypothesis the 12 UV-inactivated virus was not able to induce a protective immune response. 13
How long can an attenuated mutant like ∆m01-17+m144-158-MCMV persist after 14 resolution of lytic infection? Although we could not reactivate the virus and did not get definitive 15 data in respect to genome persistence, we assume that the virus genome persists at a very low 16 level sufficient to undergo abortive reactivation events and express immunodominant antigens 17 (25). 18 BAC cloning has made herpesvirus genomes accessible to rational mutant design. It is 19 possible to delete any combination of genes in a herpesvirus genome. Thus, the key issue in 20 herpesvirus genetics has shifted from mutant construction to the selection of genes to be targeted 21 for deletion. We had constructed additional mutants which lack other gene blocks and those 22
showing growth deficits already in vitro were not considered further (data not shown). Mutants 23 that grow poorly in cell culture are not suitable for vaccine preparation. Testing in the natural 24 host showed that severe CMV attenuation is not necessarily linked with a loss of 1 immunogenicity. Thus, our approach showed the feasibility of generating CMV vaccine strains 2 with desired properties by reverse-genetics. The mapping of essential genes in the HCMV 3 genome (18), and the mapping of genes governing cell tropism (8, 27, 48, 74), as well as those 4 mediating immune evasion, facilitates the decision on which genes or gene blocks to keep and 5 which to be removed from the genome of an HCMV vaccine candidate. Therefore, the data here 6 presented may present the first and decisive step in the generation of live-attenuated CMV 7 vaccines or vaccine vectors. 
